On May 21, 2026, West Pharmaceutical Services Inc (WST) shares rose 3.5% to $316.13. This uptick comes amidst a positive price performance, with shares having t

West Pharmaceutical Services, Inc.  WST is well positioned for growth, backed by strong demand for HVPs, expanding GLP-1 drug programs and regulatory-driven Annex 1 conversions. However, tariff impacts, destocking in generics and execution challenges at constrained European facilities are concerning.

West Pharmaceutical Services said on Wednesday it has ​restored operations across its sites after a cybersecurity attack earlier this ‌month and expects the incident to have no material impact on its 2026 financial outlook.

West Pharmaceutical Services said on Friday its operations were steadily recovering after a cyberattack ​earlier this month disrupted manufacturing and logistics ‌globally.

West Pharmaceutical Services, Inc. (WST) Presents at Bank of America Global Healthcare Conference 2026 Transcript

West Pharmaceutical Services Inc. (NYSE:WST) on Monday disclosed a material cybersecurity attack on May 7, saying an unauthorized party exfiltrated data and encrypted certain systems.

Investors interested in Medical - Dental Supplies stocks are likely familiar with Align Technology (ALGN) and West Pharmaceutical Services (WST). But which of these two stocks presents investors with the better value opportunity right now?

West Pharmaceutical (WST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

From a technical perspective, West Pharmaceutical Services, Inc. (WST) is looking like an interesting pick, as it just reached a key level of support. WST's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

West Pharmaceutical Services maintains dominant market share in injectable drug delivery, underpinned by a wide moat and robust regulatory positioning. WST reported strong Q1 2026 results, with revenue up 21% and adjusted EPS up 46.9%, prompting a guidance raise and share price rebound. Key growth drivers include biologics market expansion, GLP-1 drug demand, and Annex 1 regulatory upgrades, supporting recurring revenue and margin strength.